Low anti‐HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen‐negative patients

Low anti‐HBc serum levels at the time of therapy cessation were linked to a higher relapse risk in predominantly HBeAg‐positive cohorts. We investigated the association of anti‐HBc levels with relapse in HBeAg‐negative patients.

[1]  M. Buti,et al.  PREDICTION OF SUSTAINED RESPONSE AFTER NUCLEO(S)TIDE ANALOGUE CESSATION USING HBSAG AND HBCRAG LEVELS - A MULTICENTER STUDY (CREATE). , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  M. Yuen,et al.  Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation , 2020, Gut.

[3]  F. Zoulim,et al.  Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg‐negative chronic hepatitis B , 2020, Journal of viral hepatitis.

[4]  M. Buti,et al.  Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference , 2019, Hepatology.

[5]  Yasuhito Tanaka,et al.  Combining hepatitis B core‐related and surface antigens at end of nucleos(t)ide analogue treatment to predict off‐therapy relapse risk , 2018, Alimentary pharmacology & therapeutics.

[6]  H. Janssen,et al.  Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  Chiun Hsu,et al.  Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. , 2018, Journal of hepatology.

[8]  M. Manns,et al.  Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients , 2018, The Journal of infectious diseases.

[9]  T. Tseng,et al.  Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B. , 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

[10]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[11]  V. Wong,et al.  Infection and Cancer: The Case of Hepatitis B. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Cholongitas,et al.  Discontinuation of oral antivirals in chronic hepatitis B: A systematic review , 2016, Hepatology.

[13]  William M. Lee,et al.  Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. , 2016, Gastroenterology.

[14]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[15]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[16]  H. Wedemeyer,et al.  Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  Ding‐Shinn Chen,et al.  Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  Q. Ning,et al.  Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues , 2015, Gut.

[19]  Hong Tang,et al.  Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon , 2015, Theranostics.

[20]  N. Xia,et al.  Antibody to Hepatitis B Core Antigen Levels in the Natural History of Chronic Hepatitis B , 2014, Medicine.

[21]  M. Yuen,et al.  Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  S. Kent,et al.  Downregulation of Interleukin-18-Mediated Cell Signaling and Interferon Gamma Expression by the Hepatitis B Virus e Antigen , 2014, Journal of Virology.

[23]  C. Chu,et al.  Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients , 2013, Hepatology.

[24]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[25]  C. Aspord,et al.  Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection , 2012, Hepatology.

[26]  O. Yokosuka,et al.  Hepatitis B virus e antigen physically associates with receptor-interacting serine/threonine protein kinase 2 and regulates IL-6 gene expression. , 2012, The Journal of infectious diseases.

[27]  Ding‐Shinn Chen,et al.  Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients , 2012, Gut.

[28]  Jia-Horng Kao,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.

[29]  F. Zoulim,et al.  Selection of chronic hepatitis B therapy with high barrier to resistance. , 2012, The Lancet. Infectious diseases.

[30]  J. Hayashi,et al.  Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[31]  L. Lesmana,et al.  Diagnostic accuracy of transient elastography (FibroScan) versus the aspartate transaminase to platelet ratio index in assessing liver fibrosis in chronic hepatitis B: The role in primary care setting , 2011, Journal of Clinical Pathology.

[32]  S. Lewin,et al.  Regulation of Toll‐like receptor‐2 expression in chronic hepatitis B by the precore protein , 2007, Hepatology.

[33]  Tzu-Hsing Kuo,et al.  Human Hepatitis B Viral e Antigen Interacts with Cellular Interleukin-1 Receptor Accessory Protein and Triggers Interleukin-1 Response* , 2006, Journal of Biological Chemistry.

[34]  G. Getz.  Thematic review series: the immune system and atherogenesis. Bridging the innate and adaptive immune systems. , 2005, Journal of lipid research.

[35]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[36]  M. Chen,et al.  Role of B cells in antigen presentation of the hepatitis B core. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A Valli,et al.  Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. , 1990, Journal of immunology.

[38]  C. Dolea,et al.  World Health Organization , 1949, International Organization.